ViVac

Company Overview

Snapshot

Founded in January 2023 by Michael Vaknin, Lior Nissim, and Chezy Barenholtz, ViVac operates with 1–10 employees. The company is currently in the Pre-Funding stage, developing a nucleic acid-based vaccine platform.

Business overview

ViVac is a synthetic biology company developing a revolutionary viral vaccine platform. This platform aims to immunize against all viral proteins by safely and precisely mimicking actual viral infections. The technology is designed to offer more robust and long-lasting immunity compared to mRNA/DNA and traditional vaccines, while maintaining cost-effective production and scalability to address new viral threats. ViVac operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology, Drug Delivery, and Pharmaceuticals.

Strategic signal

In November 2025, ViVac appointed Keren Leshem as Chief Executive Officer. This strategic leadership addition signals the company's intent to strengthen its executive team and accelerate the advancement of its RNA-Lipid Nanoparticle immunotherapy platform, indicating a focus on commercialization and further development of its core technology.

Company Intelligence Q&A

What is ViVac's core technology?

ViVac is developing a nucleic acid-based vaccine platform designed to provide robust and long-lasting immunity by mimicking viral infections. This platform aims to be more effective than traditional mRNA/DNA vaccines while remaining cost-efficient and scalable.

When was ViVac founded and by whom?

ViVac was founded in January 2023 by Michael Vaknin, Lior Nissim, and Chezy Barenholtz, who are experts in synthetic biology and nano drug delivery.

What is ViVac's current product development focus?

ViVac is currently in the R&D stage, developing a nucleic-acid-based viral vaccine for RSV and Hepatitis C, leveraging its RNA-Lipid Nanoparticle immunotherapy platform.

What significant leadership change occurred at ViVac?

In November 2025, ViVac appointed Keren Leshem as Chief Executive Officer. This appointment is intended to strengthen the company's leadership and advance its RNA-Lipid Nanoparticle immunotherapy platform.

In which markets does ViVac operate?

ViVac operates globally, focusing on the Health Tech & Life Sciences sector, with specific applications in Pharma & Medical Biotechnology, Drug Delivery, and Pharmaceuticals.